CTRI/2020/04/024459
Not yet recruiting
Phase 1
Pharmaceutical Analytical and Interventional study of Darvyadi Granules in Iron Deficiency Anaemia-A Pilot Study - DGIDA-19
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Health Condition 1: D508- Other iron deficiency anemiasHealth Condition 2: D508- Other iron deficiency anemias
- Sponsor
- Parul University
- Status
- Not yet recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Patient fulfilling screening parameters.
- •Age limit 18\-70 years irrespective of religion, socioeconomic, marital status and gender
- •Hb% \- Between 8 gm% and 11gm%
Exclusion Criteria
- •Anemia other than Iron deficiency anemia, Sickle cell anemia.
- •Patients suffering from systemic disorders like tuberculosis, HIV, Leprosy and any malignancies.
- •Pregnant and Lactating Woman.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
A Clinical trial to Study the Effects of Two Drugs in patients of Diabetes Mellitus(type -II )Health Condition 1: E119- Type 2 diabetes mellitus without complicationsCTRI/2018/09/015808ational Institute of Ayurveda Jaipur30
Not yet recruiting
Phase 3
Comparative Clinical Study of Kariradi Vaginal Wash and Clotrimazole in ShwetapradarHealth Condition 1: N761- Subacute and chronic vaginitisCTRI/2024/07/069717DrApurva Chandrakant Karande
Not yet recruiting
Phase 2
Gandhashma Parpati in treatment of Grahani roga.Health Condition 1: K319- Disease of stomach and duodenum, unspecifiedCTRI/2024/07/071567Post Graduate Institute of Ayurved, Jodhpur, Rajasthan
Active, not recruiting
Not Applicable
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.Rheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2012-000535-36-CZAbbott GmbH & Co. KG100
Active, not recruiting
Not Applicable
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.Rheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2012-000535-36-DEAbbVie Deutschland GmbH & Co. KG100